Singapore Medical Device Registration

In Singapore, Singapore Medical Device Registration is a process governed by the Health Sciences Authority. One of the most important regulatory references for manufacturers is the HSA Guidance document GN-15: Guidance on Medical Device Product Registration. The latest Revision 13, released in March 2026, clarifies the mandatory registration requirements for medical devices under the Health Products Act. The document outlines how medical devices are evaluated for quality, safety, and performance based on their specific Medical Device Risk Classification before being supplied in the Singapore market. To streamline the submission process, manufacturers must use the HSA SHARE Platform for all electronic applications. Furthermore, while Singapore maintains independent standards, it is helpful to note how local requirements align with regional frameworks, such as Regulatory Reliance Malaysia, to ensure broader ASEAN compliance. Understanding this guidance is essential for manufacturers seeking regulatory approval and successful market entry.

WHAT ARE THE LATEST UPDATES IN GN-15 PRODUCT SINGAPORE MEDICAL DEVICE REGISTRATION ?

Singapore Medical Device Registration is the regulatory process through which the Health Sciences Authority evaluates technical documentation to ensure that a device meets the essential principles of safety and performance. As outlined in the HSA Guidance GN-15, all medical devices including In Vitro Diagnostic (IVD) devices must be registered under the Health Products Act before they can be supplied in Singapore, unless they fall under specific exemptions. The level of regulatory assessment is strictly determined by the Medical Device Risk Classification, ranging from Class A (low risk) to Class D (high risk). Devices with a higher risk profile require more detailed evaluation and supporting documentation. To facilitate this, manufacturers must submit their applications via the HSA SHARE Platform. Additionally, for companies looking to expand across Southeast Asia, understanding the Regulatory Reliance Malaysia can be beneficial for harmonizing documentation across both markets. Mastering these requirements is a critical step for ensuring a smooth path to market approval.

RISK CLASSIFICATION: THE FOUNDATION OF COMPLIANCE

Singapore follows a four-tier risk classification system based on the potential risk posed by a medical device.

Class A – Low Risk

Examples include basic medical equipment such as wheelchairs or tongue depressors. These devices are generally exempt from product registration but must be listed in the HSA database.

Class B – Low to Moderate Risk

Examples include devices such as hypodermic needles or suction equipment. These devices require standard product registration with moderate regulatory review.

Class C – Moderate to High Risk

Examples include ventilators and bone fixation plates. These devices require more detailed technical evaluation due to increased patient risk.

Class D – High Risk

Examples include life-sustaining or implantable devices such as heart valves and implantable defibrillators. These devices undergo the highest level of regulatory scrutiny. Correct classification is the first step in determining the appropriate registration route.

SINGAPORE MEDICAL DEVICE REGISTRATION STREAMLINED EVALUATION ROUTES

The Health Sciences Authority applies a confidence-based evaluation framework, where regulatory approvals from trusted international agencies can significantly shorten review timelines.

Recognized reference agencies include:

• U.S. Food and Drug Administration (FDA)

• Health Canada

• Pharmaceuticals and Medical Devices Agency

• Therapeutic Goods Administration

• EU Notified Bodies under the EU Medical Device Regulation

Based on the availability of prior approvals, HSA offers several evaluation pathways.

1. Full Evaluation Route

Used when there are no approvals from reference regulatory authorities. This route requires complete technical documentation and full assessment, resulting in longer review timelines.

2. Abridged Evaluation Route

Applicable when the device is approved by at least one reference regulatory authority. Manufacturers can submit summaries of key studies and evaluation reports, reducing review time.

3. Expedited Evaluation Route

Used for Class C or Class D devices with multiple reference approvals and established safety history, allowing faster regulatory review.

4. Immediate Registration Route

Available for Class B devices or certain standalone medical mobile applications that meet strict safety requirements. Devices are listed immediately on the Singapore Medical Device Register after submission.

THE DIGITAL MANDATE: SHARE PLATFORM

A major regulatory development highlighted in GN-15 Revision 13 is the full implementation of the Singapore Health Product Access and Regulatory E-System (SHARE). This platform serves as the central digital portal for regulatory interactions with the Health Sciences Authority.

Through SHARE, manufacturers must:

• Submit product registration applications

• Upload technical documentation

• Pay regulatory fees

• Track application progress

Once approved, devices are automatically listed in the Singapore Medical Device Register (SMDR).

REGULATORY RELIANCE: COLLABORATION WITH MALAYSIA

One of the significant updates in GN-15 Revision 13 is the introduction of a Regulatory Reliance program with Malaysia. Devices already registered with the Medical Device Authority (MDA) can qualify for the Abridged Evaluation Route in Singapore.

Key requirements include:

• The device must be registered with the Malaysian MDA.

• The intended use must be identical to the intended use in Singapore.

• The product must have undergone assessment by a recognized Conformity Assessment Body.

Exclusions

This reliance pathway does not apply to:

• Borderline medical products

• Devices incorporating registrable medicinal substances

This initiative helps manufacturers expand more efficiently across Southeast Asia.

RAPID MARKET ACCESS FOR MEDICAL SOFTWARE

Digital health solutions are growing rapidly, and GN-15 Revision 13 addresses this by clarifying pathways for standalone medical mobile applications.

These applications may qualify for:

• Immediate Class B Registration (IBR)

• Immediate Class C Registration (ICR)

If eligible, the device is immediately listed on the SMDR after submission and payment.

Eligibility conditions include:

• No reported deaths linked to the device

• No serious deterioration in health globally

• No field safety corrective actions or recalls in the past three years

However, manufacturers must note that HSA performs post-submission verification. If an application is later found to be ineligible or incorrectly submitted, the registration will be cancelled and fees will not be refunded.

KEY COMPLIANCE RESPONSIBILITIES FOR MANUFACTURERS

Manufacturers must maintain compliance even after product registration.

1. Algorithmic Transparency for Software

For software-based devices, manufacturers must provide:

• Software verification and validation documentation

• Cybersecurity risk management evidence

2. Stop-Clock Mechanism

When HSA requests additional information, the review timeline pauses until the manufacturer responds. Delayed responses can significantly extend approval timelines.

3. Post-Market Obligations

Registered devices must pay an annual retention fee to remain listed on the Singapore Medical Device Registration . Failure to pay results in automatic cancellation, making further supply illegal.

4. Change Notification

Any change affecting safety, quality, or performance must be reported to HSA through a Change Notification submission.

Conclusion

The HSA Guidance GN-15 (Revision 13) provides a structured regulatory pathway for medical device manufacturers seeking access to the Singapore market. By implementing digital submission through the HSA SHARE Platform, introducing Regulatory Reliance Malaysia to streamline regional approvals, and establishing faster pathways for digital health technologies, Singapore continues to modernize its medical device regulatory framework. For manufacturers, understanding the specific Medical Device Risk Classification of their products and maintaining comprehensive technical documentation is critical for a successful Singapore Medical Device Registration . By following the GN-15 guidance and maintaining robust post-market compliance practices, companies can efficiently bring safe and innovative medical technologies to Singapore’s healthcare system while meeting the highest regulatory standards.

HOW MORULAA CAN HELP

Morulaa streamlines the Singapore registration process by expertly categorizing your device into the correct risk class (A through D) and identifying the fastest evaluation route based on your existing international approvals. By actively monitoring the HSA guidance portal and the SHARE platform, Morulaa ensures your submission meets the latest digital mandates and technical requirements for cybersecurity and algorithmic transparency. Your team acts as a strategic lead, utilizing programs like the Malaysia Regulatory Reliance pathway to reduce review timelines and ensure your product is legally listed on the Singapore Medical Device Register.